Trial Profile
A Multicenter, Open Label Single Arm Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in HER2 Overexpressing Local Advanced or Metastatic Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Disitamab vedotin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors RemeGen
- 12 Jan 2022 Status changed from active, no longer recruiting to completed.
- 17 Jun 2020 Results published in the RemeGen Media Release.
- 04 Jun 2020 Status changed from recruiting to active, no longer recruiting.